GlassScriptPhysician profile
April Huggler
NPI 1265092449
$5,056.71
in general payments reported to CMS, 2019-2025
31 companies · $1,271 in 2025
The $1,271 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $484 · 2022: $632 · 2023: $1,363 · 2024: $1,307 · 2025: $1,271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,941.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $829.72 | 2022-2025 | |
| Novo Nordisk INC | $788.32 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $648.70 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $489.91 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $417.33 | 2021-2025 | |
| Lilly USA, LLC | $323.49 | 2021-2025 | Zepbound, Mounjaro |
| Exact Sciences Corporation | $293.10 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.58 | 2021-2025 | Jardiance |
| Dexcom, INC. | $143.95 | 2024-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $122.71 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $101.43 | 2021-2024 | Austedo Xr, Ajovy |
| Bayer Healthcare Pharmaceuticals INC. | $83.50 | 2023-2024 | |
| Currax Pharmaceuticals LLC | $75.23 | 2024-2025 | Contrave |
| Dynavax Technologies Corporation | $64.38 | 2024-2025 | Heplisav-B |
| Kowa Pharmaceuticals America, INC. | $60.90 | 2023-2025 | Zoryve, Livalo, Seglentis |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $60.65 | 2024-2025 | Veozah |
| Biohaven Pharmaceuticals, INC. | $45.79 | 2021 | |
| Novartis Pharmaceuticals Corporation | $44.72 | 2022-2023 | |
| Si-Bone, INC. | $32.43 | 2024 | |
| Boston Scientific Corporation | $32.31 | 2024 | |
| Merck Sharp & Dohme LLC | $30.12 | 2022-2025 | Capvaxive, Gardasil 9, M-M-R II |
| Amgen INC. | $29.16 | 2022-2025 | Repatha |
| Stryker Corporation | $26.64 | 2023 | Vitoss |
| Tonix Medicines, INC. | $18.08 | 2025 | Tonmya |
| Xeris Pharmaceuticals, INC. | $17.56 | 2024 | Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company LTD. | $16.87 | 2022 | |
| Ibsa Pharma INC. | $16.70 | 2024 | Licart, Tirosint |
| Otsuka America Pharmaceutical, INC. | $16.04 | 2023 | Nuedexta |
| Sumitomo Pharma America, INC. | $15.20 | 2025 | Gemtesa |
| Phadia US INC. | $14.59 | 2023 | Immunocap |
| Genentech USA, INC. | $13.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Huggler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.